Transgene SA - Product Pipeline Review - 2015
Summary
Global Markets Directs, ‘Transgene SA - Product Pipeline Review - 2015, provides an overview of the Transgene SAs pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Transgene SAs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news and deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Transgene SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Transgene SAs human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Transgene SAs pipeline products
Reasons to buy
- Evaluate Transgene SAs strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Transgene SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Transgene SAs RandD portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Transgene SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Transgene SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Transgene SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Transgene SA Snapshot 5
Transgene SA Overview 5
Key Information 5
Key Facts 5
Transgene SA - Research and Development Overview 6
Key Therapeutic Areas 6
Transgene SA - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Transgene SA - Pipeline Products Glance 12
Transgene SA - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Transgene SA - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Transgene SA - Drug Profiles 15
TG-4010 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
pexastimogene devacirepvec 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
TG-1042 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
TG-4001 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
MVA-TB 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
TG-1050 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
TG-3003 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
TG-6002 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Transgene SA - Pipeline Analysis 27
Transgene SA - Pipeline Products by Target 27
Transgene SA - Pipeline Products by Route of Administration 28
Transgene SA - Pipeline Products by Molecule Type 29
Transgene SA - Pipeline Products by Mechanism of Action 30
Transgene SA - Recent Pipeline Updates 31
Transgene SA - Dormant Projects 41
Transgene SA - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
TG-1042 42
Transgene SA - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List Of Tables
List of Tables
Transgene SA, Key Information 5
Transgene SA, Key Facts 5
Transgene SA - Pipeline by Indication, 2015 7
Transgene SA - Pipeline by Stage of Development, 2015 8
Transgene SA - Monotherapy Products in Pipeline, 2015 9
Transgene SA - Partnered Products in Pipeline, 2015 10
Transgene SA - Partnered Products/ Combination Treatment Modalities, 2015 11
Transgene SA - Phase II, 2015 12
Transgene SA - Phase I, 2015 13
Transgene SA - Preclinical, 2015 14
Transgene SA - Pipeline by Target, 2015 27
Transgene SA - Pipeline by Route of Administration, 2015 28
Transgene SA - Pipeline by Molecule Type, 2015 29
Transgene SA - Pipeline Products by Mechanism of Action, 2015 30
Transgene SA - Recent Pipeline Updates, 2015 31
Transgene SA - Dormant Developmental Projects,2015 41
Transgene SA - Discontinued Pipeline Products, 2015 42
Transgene SA, Subsidiaries 43
List Of Figures
List of Figures
Transgene SA - Pipeline by Top 10 Indication, 2015 7
Transgene SA - Pipeline by Stage of Development, 2015 8
Transgene SA - Monotherapy Products in Pipeline, 2015 9
Transgene SA - Partnered Products in Pipeline, 2015 10
Transgene SA - Pipeline by Top 10 Target, 2015 27
Transgene SA - Pipeline by Top 10 Route of Administration, 2015 28
Transgene SA - Pipeline by Top 10 Molecule Type, 2015 29
Transgene SA - Pipeline Products by Top 10 Mechanism of Action, 2015 30
